Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.57 |
| ▸ | ICMT | O60725 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 11/20 | 0.49 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | DNM2 | P50570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13131369 | 0.87 | CDC25A (0.72) | CDC25AICMTCNR2CNR1DNM2 | |
| SCHEMBL23269921 | 0.85 | CDC25A (0.65) | CDC25AICMTCNR2CNR1DNM2 | |
| SCHEMBL12052564 | 0.84 | CDC25A (0.60) | CDC25AICMTCNR2CNR1HDAC3 | |
| SCHEMBL16259057 | 0.83 | ICMT (0.61) | CDC25AICMTCNR2HDAC3DNM2 | |
| SCHEMBL10181834 | 0.83 | CDC25A (0.58) | CDC25AICMTCNR2CNR1 | |
| SCHEMBL13131360 | 0.82 | CDC25A (0.54) | CDC25AICMTCNR2CNR1 | |
| SCHEMBL10650270 | 0.82 | CNR2 (0.58) | CDC25AICMTCNR2CNR1 | |
| SCHEMBL3070123 | 0.81 | MEN1 (0.51) | CDC25AICMTCNR2CNR1 | |
| SCHEMBL13131371 | 0.80 | CDC25A (0.56) | CDC25AICMTCNR2CNR1HDAC3 | |
| SCHEMBL88821 | 0.80 | CNR2 (0.57) | CDC25AICMTCNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | CDC25A 3179/4885ICMT 1532/4885CNR2 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.